Global drug development in cancer: A cross-sectional study of clinical trial registries

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 895-900

  Seruga, B ^a   Hertz, P C ^a   Le, L W ^a   Tannock, I F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; Drug development; Global

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; DEVELOPED COUNTRY; DRUG RESEARCH; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REGISTER; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DRUG DISCOVERY; FEMALE; GEOGRAPHY; HUMANS; INCIDENCE; MALE; NEOPLASMS; PREVALENCE; REGISTRIES; SURVIVAL ANALYSIS; WORLD HEALTH;

EID: 77951964372     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp403     Document Type: Article

References (22)

1. International Agency on Research of Cancer. GLOBOCAN 2002. http://www-dep.iarc.fr/(8 November 2009, date last accessed).
2. Population in 1999 and 2000: All Countries. United Nations. Population Division: Department of Economic and Social Affairs, http://www.un.org/popin/popdiv/pop1999-00.pdf (10 November 2009, date last accessed). Source: World Population Prospects: The 1998 Revision. Vol. I: Comprehensive Tables (United Nations publication, Sales No. E.99.XIII.9).
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
4. World Health Organization. Global burden of disease. http://www.who.int/healthinfo/global_burden_disease/en/(10 January 2009, date last accessed).
5. De Angelis C, Drazen JM, Frizelle FA et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351(12): 1250-1251.
6. De Angelis CD, Drazen JM, Frizelle FA et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. N Engl J Med 2005; 352(23): 2436-2438.
7. Booth CM, Cescon DW, Wang L et al. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008; 26: 5458-5464.
8. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006; 25(2): 420-428.
9. Trouiller CP, Olliaro P, Torreele E et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002; 359(9324): 2188-2194.
10. World Health Organization. Spending on health: a global overview. http://www.who.int/mediacentre/factsheets/fs319/en/(10 January 2009, date last accessed).
11. World Health Organization. International Clinical Trials Registry Platform (ICTRP). http://www.who.int/ictrp/en/(5 July 2008, date last accessed).
12. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and non-for-profit organizations: 2000-2005. JAMA 2006; 295(19): 2270-2274.
13. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res 2002; 2(1): 18.
14. Rochon PA, Gurwitz JH, Simms RW et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Ann Intern Med 1994; 154(2): 157-163. Volume 21 | No. 4 | April 2010 doi:10.1093/annonc/mdp403 | 899 original article Annals of Oncology
15. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24(14): 2137-2150.
16. Extramural Committee to Assess Measures of Progress Against Cancer. Measurement of progress against cancer. J Natl Cancer Inst 1990; 82: 825-835.
17. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
18. Tas F. The contribution of countries and world regions in productivity of oncological publication. Ann Oncol 2008; 19(11): 1962-1968.
19. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676
20. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019.
21. Booth C. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm. J Clin Oncol 2008; 26(28): 4693-4694.
22. Danaei G, Vander Hoorn S, Lopez AD et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366(9499): 1784-1793.